

Scientific Poster Presentations, III

Wednesday, October 15

Convention Center:

Exhibit Hall 5

8:00 a.m.–10:00 a.m.

ENCORE PRESENTATIONS

Abstracts marked with an "E" are Encore Presentations. Encore Presentations undergo the same peer-review process as all other presentations, but they may have been presented elsewhere or published in abstract form before the 2014 Annual Meeting.

AWARDS COMPETITION

Abstracts marked with an "F" are finalists for the Best Student Poster, Best Resident and Fellow Poster, and Best Paper awards. These papers were selected by special panels of reviewers. Award winners for the Best Student Poster and Best Resident and Fellow Poster will be announced at 1:00 p.m. on Monday, October 13, in the Austin Convention Center, Exhibit Hall 5. The award winner for the Best Paper will be announced at 9:45 a.m. on Tuesday, October 14, in Exhibit Hall 5.

ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoconomics, and pharmacoepidemiology.

Adult Medicine

1. Tolvaptan for euvolemic and hypervolemic hyponatremia in the acute care setting.

Dr. Jacqueline L. Olin, MS, Pharm.D., BCPS, CDE, CPP, FASHP¹, Dr. Gwen Mitchell, Pharm.D., BCPS², Dr. Henry Cremisi, M.D.³; (1)Wingate University School of Pharmacy, Wingate, NC; (2)Department of Pharmacy, Novant Health Matthews Medical Center, Matthews, NC; (3)Novant Health Inpatient Care Specialists, Novant Health Matthews Medical Center, Matthews, NC

2. Evaluation of hypoglycemia associated with continuation of glyburide during hospitalization.

Georgia Keriazes, PharmD, BCPS, BCOP, Dhaval Jivanji, student researcher, Sarah A. Treadway, PharmD, BCPS, Samantha Bailey, PharmD, BCPS; Lakeland Regional Medical Center, Lakeland, FL

7. Association of loop diuretic dose at discharge on 30 day readmission rates in acutely decompensated heart failure patients.

Ashley Woodruff, PharmD, BCPS¹, Ashley Dorward, PharmD, BCPS², Carolyn Hempel, PharmD, BCPS¹, William Loeffler, PharmD, MBA³; (1)State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (2)Buffalo General Medical Center, Buffalo, NY; (3)D'Youville College School of Pharmacy, Buffalo, NY

Ambulatory Care

10. Medication Errors Prevented by the Medication Therapy Management Clinic (MTMC).

*Tiffany Scott-Horton, PharmD, BCACP*¹, Mansi Shah, PharmD, BCACP, CDE², Jessica Tilton, PharmD, BCACP³; (1)Pharmacy Practice, University of Illinois at Chicago, Chicago; (2)University of Illinois at Chicago; (3)University of Illinois at Chicago, Chicago, IL

12E. Simvastatin prescribing practices before and after the U.S. FDA updates to the 2011 simvastatin dosing standards.

*Rhianna Tuchscherer, PharmD*¹, Vahram Ghushchyan, PhD², Richard Allen, M.S.³, Kavita V. Nair, PhD⁴, Joseph Saseen, Pharm.D.⁵; (1)School of Medicine, Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, MN; (2)American University of Armenia, Armenia; (3)Peak Statistical Services, Evergreen, CO; (4)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; (5)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

13. Atypical Antipsychotic Use and Annual Screening for Diabetes in a Patient Centered Medical Home. *Dr. April Hinds, PharmD*, Dr. Lois Coulter, PharmD, Dr. Jonell Hudson, PharmD, Dr. Victoria Seaton, PharmD; College of Pharmacy, University of Arkansas for Medical Sciences, Fayetteville, AR

16E. Evaluation of a pharmacist-led bedside medication delivery service for cardiology patients at hospital discharge.

*Stephanie Roberts, Pharm.D.*¹, Julianna Burton, Pharm.D.¹, Pamela Mendoza, Pharm.D.², Patricia Poole, PharmD³, Machel Wilson, PhD⁴; (1)Pharmacy, UC Davis Medical Center, Sacramento, CA; (2)University of California, Davis Health System, Sacramento, CA; (3)Cares Community Health, Sacramento, CA; (4)University of California, Davis Medical Center, Sacramento, CA

Cardiovascular

21. Readmission rates in patients with post-operative atrial fibrillation after cardiothoracic surgery and the impact of pharmacotherapy.

Long To, PharmD¹, James S. Kalus, PharmD, BCPS, (AQ-Cardiology)¹, Dr. Carrie Nemerovski, PharmD², *Dr. Douglas L. Jennings, PharmD, AACC, BCPS, (AQ-Cardiology)*³; (1)Henry Ford Hospital, Detroit, MI; (2)Henry Ford Hospital; (3)Nova Southeastern University

22. Effect of Oral P2Y₁₂ Receptor Inhibitors in Acute Coronary Syndromes Treated With and Without Percutaneous Coronary Intervention: A Meta-Analysis of Nonsmokers.

*William L. Bailey, PharmD*¹, Firoozeh S. Salek, PharmD, PhD², Udaya S. Tantry, PhD³, Kevin P. Bliden, BS, MBA³, Paul A. Gurbel, MD³; (1)St. Louis College of Pharmacy, St. Louis, MO; (2)Department of Pharmacy, Robert Wood Johnson University Hospital, Rahway, NJ; (3)Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Baltimore, MD

23. Predictors of pocket hematoma following permanent pacemaker or implantable cardiac device implantation.

*Dr. Brittany Melton, Ph.D., Pharm.D.*¹, Dr. Patricia Howard, Pharm.D., FCCP, BCPS (AQ Cardiology)¹, Dr. Abby Goerdt, Pharm.D.², Dr. Jessica Casey, Pharm.D., BCPS²; (1)School of Pharmacy, University of Kansas, Lawrence, KS; (2)Department of Pharmacy Inpatient Services, University of Kansas Hospital, Kansas City, KS

24. Safety of Continuous Infusion Ketorolac in Postoperative Coronary Artery Bypass Graft Surgery Patients.

Meredith Howard, PharmD, Courtney Sheehan, PharmD, Robert Warhurst, PharmD; Department of Pharmacy, Indiana University Health, Indianapolis, IN

29. Evaluation of subtherapeutic international normalized ratio (INR) management strategies in patients with mechanical heart valves.

Dr. Kelly Bartsch, PharmD, BCPS¹, Dr. Marguerite Hevezi, PharmD, CLS, CDE², Dr. Andrea Hirsch, PharmD, BCPS, CLS², Dr. Diana Vinh, PharmD, BCPS², Dr. Tiffany Chang, PharmD², Dr. Virginia Mitchell, PharmD, BCPS, CLS²; (1)Ambulatory Care, The Ohio State University Wexner Medical Center, Columbus, OH; (2)The Ohio State University Wexner Medical Center, Columbus, OH

33. Outcomes of a Pharmacist-Managed Heart Failure Medication Titration Clinic.

Dr. Shubha Bhat, PharmD¹, Dr. Mayank Kansal, MD², Dr. Thomas Stamos, MD², Dr. George Kondos, MD², Dr. Vicki L. Groo, PharmD¹; (1)Department of Pharmacy Practice, University of Illinois at Chicago; (2)Department of Medicine, University of Illinois at Chicago

Community Pharmacy Practice

37. A Smoking Cessation Model That Integrates Social Media in Hospitalized Patients Post-Discharge.

Neha Vora, Pharm.D.¹, Roger Smalligan, MD², Rahul Chandra, MD², Shanna James, Pharm.D.¹, Rachel Basinger, Pharm.D., BCPS¹, Jill Frost, Pharm.D.¹, Christine Acker, Respiratory Therapist³, Jana Hutcherson, B.A.²; (1)Department of Pharmacy Practice, Texas Tech Health Science Center School of Pharmacy - Amarillo, Amarillo, TX; (2)Internal Medicine, Texas Tech Health Science Center School of Medicine - Amarillo, Amarillo, TX; (3)Department of Respiratory, Northwest Texas Hospital, Amarillo, TX

Critical Care

38E. Incidence of enteral nutrition intolerance in critically ill patients receiving vasopressor therapy.

Sarah Vest, PharmD¹, Diana Wells, PharmD, BCPS², Amber Hutchison, PharmD, BCPS², Christine Cicci, PharmD, BCPS¹, Jennie Swearingen, PharmD, BCPS¹; (1)East Alabama Medical Center, Opelika, AL; (2)Harrison School of Pharmacy, Auburn University, Auburn, AL

39. Knowledge about neuromuscular blocking agents for respiratory failure among medical intensive care unit nurses: a multicenter survey.

Erin N. Frazee, PharmD¹, Heather A. Personett, PharmD¹, Seth Bauer, Pharm.D., BCPS², Amy Dzierba, PharmD³, Joanna Stollings, PharmD⁴, Lindsay Ryder, PharmD⁵, Jennifer Elmer, DNP⁶, Craig Daniels, MD⁷, Sean Caples, DO⁸; (1)Mayo Clinic, Rochester, MN; (2)Department of Pharmacy, Cleveland Clinic, Cleveland, OH; (3)Department of Pharmacy, NewYork-Presbyterian Hospital, New York, NY; (4)Department of Pharmaceutical Services, Vanderbilt University Medical Center; (5)Department of Pharmacy, The Ohio State University Wexner Medical Center; (6)Department of Nursing, Mayo Clinic; (7)Pulmonary and Critical Care Medicine, Mayo Clinic; (8)Pulmonary and Critical Care medicine, Mayo Clinic

40E. Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia.

Dr. Kathryn Morbitzer, PharmD¹, Dr. J. Dedrick Jordan, MD, PhD², Dr. Emily Durr, PharmD³, Dr. Denise Rhoney, PharmD¹; (1)Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, Chapel Hill, NC; (2)Department of Neurology and Neurosurgery, University of North Carolina

at Chapel Hill School of Medicine, Chapel Hill, NC; (3)Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, NC

41. Delirium in mechanically-ventilated intensive care patients: effect of sedation and risk factors.

Marian Gaviola, PharmD¹, Karen Petros, Pharm.D.², Michael Regier, PhD³, Alison Wilson, MD⁴, John Honaker, BS³; (1)Department of Pharmaceutical Services, WVU Healthcare, Morgantown, WV; (2)West Virginia University Healthcare; (3)Department of Biostatistics, West Virginia University, Morgantown, WV; (4)Division of Trauma Acute Care Surgery, West Virginia University, Morgantown, WV

42. Patient outcomes based on hypoglycemic events during therapeutic hypothermia.

Ana Negrete, Pharm.D., BCPS¹, Yiwen Chang, Pharm.D.², Jennifer Lehneman-Smith, Pharm.D., BCPS², *Carrie S. Oliphant, Pharm.D., BCPS (AQ Cardiology)²*; (1)Pharmacy Department, Methodist University Hospital, Memphis, TN; (2)Department of Pharmacy, Methodist University Hospital, Memphis, TN

44E. The Impact of Chlorhexidine Mouthwash Prophylaxis on Ventilator-Associated Events.

Emmanuel Enwere Jr., PharmD, MS¹, Kathryn Elofson, PharmD², Anthony Gerlach, PharmD, BCPS, FCCM³; (1)The University of Texas MD Anderson Cancer Center; (2)Huntsman Cancer Hospital, University of Utah Hospitals & Clinics; (3)The Ohio State University Wexner Medical Center

Drug Information

45. Drug Information Practice and Research Network needs assessment survey.

Jennifer Phillips, Pharm.D., BCPS¹, Dianne May, B.S., Pharm.D., BCPS², J. Russell May, B.S., Pharm.D., FASHP², Erin Timpe Behnen, Pharm.D, BCPS³, Allison Bernknopf, Pharm.D., BCPS⁴, Sabrina W. Cole, Pharm.D., BCPS⁵, Cathy Ficzer, Pharm.D., BCPS⁶, Michael Gabay, Pharm.D., JD, BCPS⁷, Jennifer Nieman, B.A., Pharm.D., BCPS⁸; (1)Chicago College of Pharmacy, Midwestern University, Downers Grove, IL; (2)Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Augusta, GA; (3)Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, IL; (4)Homer Stryker M.D. School of Medicine, Ferris State University / Western Michigan University, Kalamazoo, MI; (5)Wingate University School of Pharmacy, Wingate, NC; (6)Department of Pharmacy Practice, Belmont University College of Pharmacy, Nashville, TN; (7)College of Pharmacy, University of Illinois at Chicago, Chicago, IL; (8)Department of Pharmacy Relations & Clinical Decision Support, The Nebraska Medical Center, Omaha, NE

Education/Training

47E. Rubric reliability in evaluating oral case-based presentations in a Drug-Induced Diseases elective.

Sarah A. Nisly, PharmD¹, Dr. Alex Isaacs, PharmD², Dr. Alison Walton, PharmD³, Dr. Meredith Howard, PharmD⁴; (1)Butler University College of Pharmacy and Health Sciences & Indiana University Health, Indianapolis, IN; (2)Department of Pharmacy Practice, Purdue University & Eskenazi Health, Indianapolis, IN; (3)Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis, IN; (4)Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences & Indiana University Health, Indianapolis, IN

48. Development, pilot, and quality assessment of a pharmacogenomics education program for pharmacists.

Christine M. Formea, PharmD¹, Wayne T. Nicholson, MD, PharmD², Kristen B. McCullough, PharmD¹, Julie L. Cunningham, PharmD³, Julianna A. Merten, PharmD¹, John D. Zeuli, PharmD¹, Eric T. Matey, PharmD¹, Garrett E. Schramm, PharmD¹, Kelly K. Wix, PharmD¹, Carolyn R. Vitek, MS⁴, Darcy M. Richardson, MBA⁴; (1)Hospital Pharmacy Services, Mayo Clinic, Rochester, MN; (2)Department of Anesthesiology, Mayo Clinic, Rochester, MN; (3)Department of Hospital Pharmacy Services; College of Medicine Mayo Clinic, Mayo Clinic, Rochester, MN; (4)Center for Individualized Medicine, Mayo Clinic, Rochester, MN

49. The effect of quizzes on student preparation prior to a flipped classroom.

Asad Patanwala, PharmD, Brian Erstad, PharmD, John Murphy, PharmD; Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ

50. Residency application scoring tool to predict positive onsite interviews.

Sarah A. Nisly, PharmD¹, Dr. Meredith Howard, PharmD², Dr. Alex Isaacs, PharmD³, Tate Trujillo, PharmD⁴; (1)Butler University College of Pharmacy and Health Sciences & Indiana University Health, Indianapolis, IN; (2)Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences & Indiana University Health, Indianapolis, IN; (3)Department of Pharmacy Practice, Purdue University & Eskenazi Health, Indianapolis, IN; (4)Indiana University Health, Indianapolis

51. Pharmacy resident publication success: factors of success based on abstracts from a regional meeting.

Paul Stranges, PharmD, BCPS, BCACP¹, Scott Vouri, PharmD, BCPS, CGP¹, Frances Bergfeld, PharmD Candidate, Mallory Crain, PharmD Candidate, Neha Jindal, PharmD Candidate, Megan Landrum, PharmD Candidate, Sarah Lindauer, PharmD Candidate, Zachary Mueller, PharmD Candidate, Ashley Reich, PharmD Candidate, Lince Thomas, PharmD Candidate; (1)St. Louis College of Pharmacy, St. Louis, MO

53. Incorporating Diabetes Nutrition Education into the Advanced Pharmacy Practice Experience.

Anne Ottney, PharmD; Pharmacy Practice/Family Medicine, Ferris State University/Sparrow/MSU Family Medicine Residency Program, Lansing, MI

56. Comparison of Knowledge and Confidence of Pharmacy Students and Community Members Before and After a Smoking Cessation Seminar.

Justin J. Sherman, M.C.S., Pharm.D.¹, Dr. Brett Smith, Pharm.D.²; (1)School of Pharmacy, The University of Mississippi School of Pharmacy, Jackson, MS; (2)Department of Pharmacy, G.V. (Sonny) Montgomery Veterans Affairs Medical Center, Jackson, MS

57. Assessing medical residents' knowledge on the use of inhalers.

Sara Dadayan, PharmD¹, Sarah Muench, PharmD², Holly H. Chiu, Pharm.D.³, Tania Shamoun, MD⁴; (1)Department of Pharmaceutical Services, Beaumont Hospital, Royal Oak, Royal Oak, MI; (2)Department of Pharmaceutical Services, Beaumont Hospital Royal Oak, Royal Oak, MI; (3)Beaumont Hospital, Royal Oak, MI; (4)Beaumont Hospital -Royal Oak, Royal Oak, MI

59. Preparing U.S. Pharmacists for Patient Centered Care: The ADAPT Online Education Program.

Dr. Andrea L. Pierce, PharmD¹, Dr. Leticia R. Moczygemba, PharmD, PhD¹, Dr. Michael Czar, PhD, RPh², Philip Emberley, B.Sc.(Pharm.), M.B.A., Pharm.D.³, Dr. Gary R. Matzke, PharmD¹; (1)Department of Pharmacotherapy and Outcomes Sciences, Virginia Commonwealth University School of Pharmacy, Richmond, VA; (2)Carilion New River Valley Medical Center; (3)Canadian Pharmacists Association

60. Impact of a teaching certificate program on pharmacy resident self-confidence with various aspects of academia.

Julie A. Murphy, PharmD, BCPS, FASHP, FCCP¹, Amie D. Brooks, PharmD, FCCP, BCPS, BCACP², Christy Burrows-Grandstaff, PharmD, BCPS³, Erika Michalski, M.Ed.², Lindsay Bell, PharmD Candidate², John M. Burke, PharmD, BCPS, FCCP, FASHP²; (1)University of Toledo College of Pharmacy, Toledo, OH; (2)St. Louis College of Pharmacy, St. Louis, MO; (3)St. Luke's Hospital, Chesterfield, MO

Emergency Medicine

66. Assessment of Phenytoin Loading Practices in Obese Patients in the Emergency Department and the Impact of an Emergency Medicine Pharmacist.

Dr. Abby Bailey, PharmD¹, Dr. Stephanie Baker Justice, PharmD¹, Dr. Martina Holder, PharmD¹, Ms. Natalie Walker, PharmD Candidate 2014², Ms. Penny Webber, PharmD Candidate 2014³, Dr. Kyle Weant, PharmD⁴; (1)Department of Pharmacy Services, University of Kentucky HealthCare; (2)University of Kentucky College of Pharmacy; (3)University of Kentucky College of Pharmacy; (4)Public Health Preparedness and Response, North Carolina Department of Health and Human Services

67. Identification of Rate-Limiting Steps in the Provision of Thrombolytics for Acute Ischemic Stroke.

Dr. Elise Fleishaker, PharmD¹, Dr. Abby Bailey, PharmD², Dr. Stephanie Baker, PharmD¹, Dr. Kyle Weant, PharmD³; (1)University of Kentucky Chandler Medical Center; (2)Department of Pharmacy Services, University of Kentucky HealthCare; (3)North Carolina Department of Health and Human Services

68. Evaluation of antihypertensive medications and door-to-needle time with recombinant tissue plasminogen activator for acute ischemic stroke.

Steven F. Nerenberg, Pharm.D., Craig Cocchio, Pharm.D., BCPS; Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ

70. Evaluation of infection rates among patients who received piperacillin/tazobactam versus cefazolin and gentamicin for type III open fracture prophylaxis in a rural medical center.

Jenessa Redfern, Pharm.D.¹, Meghan Groth, Pharm.D.², Wesley McMillian, Pharm.D.², Scott Wasilko, MD³, Craig Bartlett, MD³; (1)Pharmacy, Fletcher Allen Health Care, Burlington, VT; (2)Pharmacy, Fletcher Allen Health Care, Burlington, VT; (3)Orthopedics, Fletcher Allen Health Care

71. Evaluation of Door-to-Needle Time for Alteplase in Ischemic Stroke Before and After Primary Stroke Center Certification.

Dr. Bradford McDaniel, Pharm.D.¹, Dr. Lisa Deal, Pharm.D., BSN²; (1)Department of Pharmacy, Carilion Clinic, Roanoke, VA; (2)Carilion Clinic, Roanoke, VA

Endocrinology

75E. Significance of hypoglycemia in patients with type 2 diabetes mellitus in primary care.

Frank Lavernia, MD¹, Donna Tomky, MSN RN C-NP CDE FAADE², Theresa McGhee, BSc³, Terry Dex, PharmD⁴, Mehul Dalal, PhD⁴, Jeffrey Frimpter, MPH⁵, Wei Zhou, MSc⁶, John Stewart, MSc⁶, Aleksandra Vljajnic, MD⁴; (1)North Broward Diabetes Center, Coconut Creek, FL; (2)ABQ Health Partners, Albuquerque, NM; (3)AbsoluteCARE Medical Center, Atlanta, GA; (4)Sanofi US, Inc., Bridgewater, NJ; (5)Doctor Evidence, Santa Monica, CA; (6)Sanofi Canada, Laval, QC, Canada

78E. Insulin versus glucagon-like peptide-1 receptor agonist as first injectable therapy in primary care.

Mark Warren, MD, FACE¹, Hallie Brown, BS², Andres DiGenio, MD³, Carl Friedrichs III, MD², Jeffrey Frimpter, MPH⁴, Bryan Johnstone, PhD⁵, John Stewart, MSc⁶, Mehul Dalal, PhD⁵; (1)Physicians East, P.A.,

Greenville, NC; (2)Anasazi Medical Associates, Santa Fe, NM; (3)Isis Pharmaceuticals, Inc., Carlsbad, CA; (4)Doctor Evidence, Santa Monica, CA; (5)Sanofi US, Inc., Bridgewater, NJ; (6)Sanofi Canada, Laval, QC, Canada

79E. A clinical trial of propolis supplementation on type II diabetic patients treated with gliclazide and metformin.

Noha Hashem, MSc¹, AbdelHameed Elshamy, PhD², Maram Maher, MD³, Osama A. Badary, PhD⁴;

(1)Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University, Cairo, Egypt; (2)Department of Pharmaceutics, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; (3)Department of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University, Cairo, Egypt; (4)Department of Clinical Pharmacy, Faculty of Pharmacy, Ain shams University, Cairo, Egypt

80E. Real-world characteristics of patients with type 2 diabetes mellitus at A1C goal ($\leq 7\%$) compared with patients not at goal ($> 7\%$): the Diabetes FORWARD study.

Eric Harman, MD¹, John Stewart, MSc², Wei Zhou, MSc², Jeffrey Frimpter, MPH³, Aleksandra Vlajnic, MD⁴;

(1)Mountain Region Family Medicine, Kingsport, TN; (2)Sanofi Canada, Laval, QC, Canada; (3)Doctor Evidence, Santa Monica, CA; (4)Sanofi US, Inc., Bridgewater, NJ

81E. Demographics, clinical, and treatment patterns in African Americans with type 2 diabetes mellitus in primary care.

Theresa Cho, MD¹, Manuel Quinones, MD², Terry Dex, PharmD³, Mehul Dalal, PhD³, Jeffrey Frimpter,

MPH⁴, John Stewart, MSc⁵, Aleksandra Vlajnic, MD³; (1)Ventura County Medical Center, Ventura, CA; (2)Talbert Medical Group, Anaheim, CA; (3)Sanofi US, Inc., Bridgewater, NJ; (4)Doctor Evidence, Santa Monica, CA; (5)Sanofi Canada, Laval, QC, Canada

82. Real-world characteristics and A1C outcomes in younger (<70 years) and older (≥ 70 years) patients with type 2 diabetes mellitus: the Diabetes FORWARD study.

Andrea Videlefsky, MD¹, John Stewart, MSc², Aleksandra Vlajnic, MD³, Terry Dex, PharmD³, Mehul Dalal,

PhD³; (1)Urban Family Practice Associates, Marietta, GA; (2)Sanofi Canada, Laval, QC, Canada; (3)Sanofi US, Inc., Bridgewater, NJ

84E. Efficacy and safety of saxagliptin as monotherapy in patients with type 2 diabetes: a pooled analysis.

Boaz Hirshberg, MD¹, Brian Bryzinski, MD¹, John Xu, PhD¹, John Monyak, PhD¹, Nayyar Iqbal, MD², Jeffrey

Frye, PharmD³; (1)AstraZeneca, Wilmington, DE; (2)Bristol-Myers Squibb, Princeton, NJ; (3)AstraZeneca, Fort Washington, PA

Family Medicine

87. Survey of student pharmacists' awareness and intention to practice in patient-centered medical homes.

Dr. Andrea L. Pierce, PharmD, Dr. Leticia R. Moczygomba, PharmD, PhD, Dr. Gary R. Matzke, PharmD;

Department of Pharmacotherapy and Outcomes Sciences, Virginia Commonwealth University School of Pharmacy, Richmond, VA

89. Revisiting Project Re-Engineered Discharge (RED): The impact of a pharmacist telephone intervention on hospital readmission rates.

Michelle Mancuso, PharmD¹, Gail Sanchez, PharmD¹, Mark Douglass, PharmD²; (1)Department of Pharmacy, Boston Medical Center, Boston, MA; (2)Department of Pharmacy Practice, Northeastern University School of Pharmacy, Boston, MA

90. Evaluation of diabetes outcomes after implementation of clinical pharmacy services in an employer-sponsored family medicine clinic.

Holly Gurgle, PharmD, BCACP, CDE¹, Carrie McAdam-Marx, RPh, MS, PhD², Mukul Singhal, BS², Peter Weir, MD, MPH³; (1)Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT; (2)Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT; (3)ARUP Family Health Clinic, ARUP Laboratories, Salt Lake City, UT

91. Clinical and economic outcomes of a collaborative diabetes management program in an employer-sponsored family medicine clinic.

Holly Gurgle, PharmD, BCACP, CDE¹, Carrie McAdam-Marx, RPh, MS, PhD², Mukul Singhal, BS², Peter Weir, MD, MPH³; (1)Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT; (2)Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT; (3)ARUP Family Health Clinic, ARUP Laboratories, Salt Lake City, UT

Gastroenterology

94. Multivariate Analysis of Factors that Influence Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) after Pioglitazone Treatment.

Marina Kawaguchi-Suzuki, Pharm.D.¹, Fernando Bril, M.D.², Beverly Orsak, R.N.³, Carolina Ortiz-Lopez, M.D.³, Romina Lomonaco, M.D.², Kenneth Cusi, M.D.², Reginald Frye, Pharm.D., Ph.D.¹; (1)Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL; (2)Division of Endocrinology, Diabetes and Metabolism, College of Medicine, University of Florida, Gainesville, FL; (3)Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX

Geriatrics

98. Assessment of Medication Counseling and Medication Knowledge in an Older Adult Population in a VA Outpatient Clinic.

Jason Moss, PharmD¹, Ramonna Cvelich, PharmD², Cathleen Colon-Emeric, MD, MHS³, Jack Twersky, MD³; (1)Campbell University/Durham VA GRECC, Durham, NC; (2)Duke Regional Hospital, Durham, NC; (3)Duke University Medical Center/Durham VA GRECC, Durham, NC

99. Risk of Pneumonia in Older Adults Using Non-Benzodiazepine Hypnotics.

Stephen Jung, PharmD, BCPS¹, Michele Spence, PhD², Nina Escasa, PharmD, BCPS³, Rita Hui, PharmD, MS⁴, Eric Lee, MD⁵, Nancy Gibbs, MD⁶; (1)Department of Clinical Development, OptumRx, Irvine, CA; (2)Pharmacy Outcomes Research Group, Kaiser Permanente, Downey, CA; (3)Drug Information Services, Kaiser Permanente, Downey, CA; (4)Pharmacy Outcomes Research Group, Kaiser Permanente, Oakland, CA; (5)Department of Internal Medicine, Kaiser Permanente West Los Angeles Medical Center, Los

Angeles, CA; (6)Department of Family Practice, Kaiser Permanente Baldwin Park Medical Center, Baldwin Park, CA

100. Adverse events associated with diphenhydramine use for insomnia in the elderly.

Dr. Marissa Cavaretta, PharmD., BCPS, BCACP, Alexander Dellabella, PharmD. Candidate, Erika Goldberg, PharmD. Candidate, Alexandra Hanretty, PharmD. Candidate, Meghan Mitchell, PharmD. Candidate, Dr. Christina Rose, PharmD., BCPS, Dr. Jason Gallagher, PharmD., FCCP, BCPS; Temple University School of Pharmacy, Philadelphia, PA

Health Services Research

101. Clinical and Economic Outcomes of Pharmacist-led Anticoagulation Clinic in Hong Kong.

Ms. Siu-Ling Leung, BPharm, MCP¹, Ms. Wing-yan Kong, BPharm, MCP¹, Mr. Li-hung Mo, BPharm, MSc, BCPS¹, Ms. Pauline Chu, MPharm, MRPharmS¹, Dr. Joyce You, PharmD, BCPS²; (1)Department of Pharmacy, Tuen Mun Hospital, Hong Kong; (2)School of Pharmacy, The Chinese University of Hong Kong, Hong Kong

Hematology/Anticoagulation

104. Unfractionated heparin dosing in obese patients with venous thromboembolism.

Dr. Chau Chu, Pharm.D.¹, Dr. Lindsay Arnold, PharmD²; (1)Department of Pharmacy, Boston Medical Center; (2)Department of Pharmacy, Boston Medical Center, Boston, MA

HIV/AIDS

111. Safety and tolerability of Stribild® in an HIV-infected population in the Southeastern United States.

Caroline Derrick, PharmD¹, Celeste Caulder, PharmD¹, E. Kelly Hester, PharmD, BCPS, AAHIVP², Tyler Wagner, PharmD Candidate³, P. Brandon Bookstaver, PharmD, BCPS (AQ-ID), AAHIVP⁴; (1)South Carolina College of Pharmacy, University of South Carolina, Columbia, SC; (2)Auburn University Harrison School of Pharmacy, Auburn, AL; (3)University of South Carolina Honors College, Columbia, SC; (4)Department of Clinical Pharmacy & Outcomes Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC

Infectious Diseases

116. Assessment of a vancomycin dosing protocol to achieve goal serum concentrations.

Kelly M. Percival, PharmD¹, Jena K. Cummins, PharmD¹, Kristine M. Valenti, PharmD¹, Stacy E. Schmittling, PharmD, BCPS¹, Scott J. Bergman, PharmD, BCPS²; (1)Department of Pharmacy, St. John's Hospital, Springfield, IL; (2)Department of Pharmacy Practice, Southern Illinois University Edwardsville School of Pharmacy, Springfield, IL

117. Antibiotic stewardship within the intensive care unit.

Marcus Lockhart, Pharm.D.¹, Rani Madduri, Pharm.D.¹, Keith Goldstein, MD.², Thom K. Nguyen, Pharm.D.³, Philip Coco, Pharm.D.¹, Navin Philips, Pharm.D., BS²; (1)Department of Pharmaceutical Services, Hunterdon Medical Center, Flemington, NJ; (2)Hunterdon Medical Center, Flemington, NJ; (3)Department of Pharmacy Practice and Administration, Rutgers, The State University of New Jersey, Piscataway, NJ

123. Antibiotic Treatment Duration in Male Veterans with Urinary Tract Infections.

Dr. Michael Lorenz, Pharm.D.¹, *Patrick Finnegan, Pharm.D., BCPS*²; (1)Department of Pharmacy, Saint Louis VA Healthcare System, Saint Louis, MO; (2)John Cochran Division, VA St. Louis Health Care System, St. Louis, MO

124E. Regional and seasonal variations in *Clostridium difficile* infections in United States hospitals, 2001 to 2010.

*Kelly Reveles, Pharm.D., Ph.D.*¹, Dr. Grace Lee, Pharm.D.², Dr. Natalie Boyd, M.S., Pharm.D.², Christopher Frei, Pharm.D., M.S.²; (1)College of Pharmacy, The University of Texas at Austin, TX; (2)College of Pharmacy, The University of Texas at Austin, San Antonio, TX

125E. The Rise of Hospitalizations Due to Staphylococcus Aureus Skin and Soft Tissue Infections Among United States Children From 2001 to 2010.

Grace C. Lee, Pharm.D, BCPS¹, *Kelly Reveles, Pharm.D., Ph.D.*², *Natalie Boyd, PharmD, MS*¹, Christopher Frei, Pharm.D., M.S.¹; (1)College of Pharmacy, The University of Texas at Austin, San Antonio, TX; (2)College of Pharmacy, The University of Texas at Austin, TX

126. Critically-Ill Recipients of Weight-Based Fluconazole Meeting Drug-Induced Liver Injury Network (DILIN) Criteria.

Merlyn L. Joseph, Pharm.D., Russell T. Attridge, Pharm.D., MSc., BCPS, Jason M. Cota, Pharm.D., MSc, Cheryl K. Horlen, Pharm.D., BCPS, Kathleen A. Lusk, Pharm.D., Rebecca L. Brady, Pharm.D., Rebecca L. Attridge, Pharm.D., MSc, BCPS; University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX

127. Real-World Outcomes of Chronic Hepatitis C Virus (HCV) Genotype 1-Infected Veterans Treated with Boceprevir- or Telaprevir-Based Therapy.

*Kruti Patel, PharmD*¹, Helen Yee, PharmD², Hui Shen, BS³, Joshua Chua, PharmD¹, Alexander Monto, MD²; (1)Department of Veterans Affairs Medical Center, San Francisco, California, San Francisco, CA; (2)Department of Veterans Affairs Hepatitis C Resource Center Program, Washington, DC; (3)University of California, San Francisco

128E. Evaluation of an Extended-Infusion Piperacillin-Tazobactam Protocol at a University Hospital.

Dr. Robert Sbertoli, PharmD, Dr. Emily Welch, PharmD, BCPS; Department of Pharmacy, Saint Louis University Hospital, St Louis, MO

Medication Safety

129. Evaluating the quality of medical mobile apps that target drug-related problems.

Mr. John Loy, B.Sc.(Pharmacy), *Dr. Kevin Yap, Ph.D., SRPharmS*; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore

130. Incidence of medication dispensing discrepancies associated with electronic medication prescribing in a university hospital internal medicine clinic.

Katharine McCarthy, Pharm.D.; Outpatient Pharmacy Department, University of Rochester Medical Center, Rochester, NY

134. Determining If Substances are Properly Dispensed of Safely and Effectively (DISPOSE).

Dr. Jaclyn Cole, Pharm.D., Dr. Melissa Ruble, Pharm.D., Dr. Rachel Franks, Pharm.D., Dr. Angela Hill, Pharm.D.; Pharmacotherapeutics and Clinical Research Department, University of South Florida College of Pharmacy, Tampa, FL

135. Use of an interactive role-play activity to educate teens about substance abuse.

Dr. Helen C. Pervanas, Pharm.D.¹, Dr. Sing Chhay, PharmD², Jennifer A. Kelleher, BA³; (1)Pharmacy Practice Department, MCPHS University, Manchester, NH; (2)MCPHS University, Norcross, GA; (3)MCPHS University, Manchester, NH

136. Medication discrepancies identified in home health patients.

Amy Myers, PharmD, BCPS¹, Dr. Jennifer Hale, PharmD², Erin Neal, Pharm.D., BCPS³, Ms. Kelsii Gerber, MS⁴, Ms. Kelly Wright, MS⁴, Dr. Amanda Mixon, MD, MS, MSPH⁵; (1)Department of Pharmacy, Vanderbilt Medical Center, Nashville, TN; (2)Vanderbilt University Medical Center; (3)Vanderbilt University Medical Center, Nashville, TN; (4)Vanderbilt University; (5)Division of General Internal Medicine and Public Health, Vanderbilt University

Nephrology

138E. Implementation of a Pharmacy Managed Erythropoiesis Stimulating Agent Prescribing Protocol in the Inpatient Setting.

Joanna Q. Hudson, Pharm.D., BCPS, FASN, FCCP, FNKF¹, Christopher K. Finch, Pharm, D., BCPS, FCCM²; (1)The University of Tennessee, University of Tennessee, Memphis, TN; (2)Pharmacy Department, Methodist University Hospital, Memphis, TN

Neurology

140E. Clinical outcomes in patients with Parkinson's disease treated with a monoamine oxidase type-B inhibitor (MAOB-I): A cross-sectional study.

Jack J. Chen, PharmD¹, Khashayar Dashtipour, MD, PhD¹, Khaled Bahjri, MD, MPH²; (1)Loma Linda University, Loma Linda, CA; (2)School of Public Health, Loma Linda University, Loma Linda, CA

141. A Mixed Treatment Comparison to Compare the Efficacy of Botulinum Toxin Type A Treatments for Upper Limb Spasticity.

Jack J. Chen, PharmD¹, Heather Walker, MD², Yi Han, PhD³, Andrea Stevens, PhD³, Kathleen Lomax, MD⁴, Michael Lee, MD²; (1)Loma Linda University, Loma Linda, CA; (2)University of North Carolina, NC; (3)WG Consulting, NY; (4)Ipsen Biopharmaceuticals Inc, NJ

142. Correlation between Unified Parkinson's Disease Rating Scale and Global Impression of Change Scales.

Jack J. Chen, PharmD, Khashayar Dashtipour, MD, PhD, Pejman Dalaie, MD, Kayvan Kani, MD, MPH, Camellia Kani, MD, MAS; Loma Linda University, Loma Linda, CA

144. Predictive performance of the Winter-Tozer and its derivative equations for estimating free phenytoin concentrations in specific patient populations.

Wendy Cheng, BSc(Pharm)¹, Tony KL Kiang, BSc(Pharm), PhD, ACPR¹, Penny Bring, BSc(Pharm), ACPR, PharmD¹, Mary HH Ensom, PharmD, FASHP, FCCP, FCSHP, FCAHS²; (1)Department of Pharmacy, Vancouver General Hospital, Vancouver, BC, Canada; (2)The University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada

Nutrition

145. Challenges of administering pancrelipase in adult pancreatitis patients.

Jackie Tran, Pharm.D.¹, Stephen Lemon Jr., Pharm.D.², Dr. Yan Zhang, Pharm.D.¹, *Abigail Antigua, Pharm.D.²*; (1)Department of Pharmacy, UF Health Shands Hospital; (2)Department of Pharmacy, UF Health Shands, Gainesville, FL

146. Reassessment of the appropriateness of parenteral nutrition therapy in adult critically ill patients after implementation of a parenteral nutrition qualification checklist.

Stephen Lemon Jr., Pharm.D.¹, Jenny Liu, Pharm.D.², Bibin Varughese, Pharm.D.², *Abigail Antigua, Pharm.D.¹*; (1)Department of Pharmacy, UF Health Shands, Gainesville, FL; (2)School of Pharmacy, University of Florida College of Pharmacy, Gainesville, FL

Other

149. Implementation of a cardiac patient medication transition pilot program: a prospective study of inpatient and outpatient clinical pharmacy services.

Julie A. Murphy, PharmD, BCPS, FASHP, FCCP¹, Sean O. P. McKee, PharmD², Rachel E. Rarus, PharmD², Michelle N. Mangan, PharmD, BCACP, CDE³, Steven J. Martin, PharmD, BCPS, FCCP, FCCM⁴; (1)University of Toledo College of Pharmacy, Toledo, OH; (2)University of Toledo Medical Center; (3)College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice, The University of Toledo, Toledo, OH; (4)Ohio Northern University

Pain Management/Analgesia

153E. Liposomal Bupivacaine Versus Elastomeric Continuous Infusion Bupivacaine Pump.

Michael Kenes, PharmD¹, Mandy Leonard, PharmD¹, Seth Bauer, Pharm.D., BCPS², Marcia Wyman, PharmD¹; (1)Cleveland Clinic; (2)Department of Pharmacy, Cleveland Clinic, Cleveland, OH

154. Correlation of Pain Scores and Opiate Requirements: A Comparison of Two Methods.

Dr. Zachariah Thomas, PharmD, Dr. Brian Faley, PharmD, Dr. Justin Kaplan, PharmD; Department of Pharmacy, Hackensack University Medical Center, Hackensack, NJ

Pediatrics

156. Effects of antithrombin during extracorporeal membrane oxygenation.

Marcia L. Buck, PharmD¹, Samuel Addison, RRT¹, Amanda Liszewski, PharmD², Gary Fang, MD³, David Kaufman, MD³; (1)University of Virginia Children's Hospital, Charlottesville, VA; (2)Department of Clinical Pharmacy Services, University of Virginia, Charlottesville, VA; (3)Department of Pediatrics, School of Medicine, University of Virginia, Charlottesville, VA

157. Pediatric hypertension: who is keeping watch?

Dr. Flora Estes, Pharm.D.; Pharmacy Practice, Texas Southern University, College of Pharmacy and Health Sciences, Houston, TX

158. Initial dosing of methadone and morphine for treatment of neonatal abstinence syndrome.

*Bethany Ibach, Pharm.D.*¹, Peter Johnson, Pharm.D., BCPS², Roshni Patel, Pharm.D.³, Diana Mendez, Pharm.D. Candidate³, Donald Harrison, Ph.D., FAPhA², Kimberly Ernst, MD⁴, Jamie Miller, Pharm.D., BCPS²; (1)Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX; (2)Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, OK; (3)University of Oklahoma College of Pharmacy, Oklahoma City, OK; (4)Department of Pediatrics, University of Oklahoma College of Medicine, Oklahoma City, OK

Pharmacoeconomics/Outcomes

160. Relationship between delays in filling prescriptions and 30-day readmission rate among patients discharged for heart failure: a retrospective study.

Yang Fan, Pharm.D., Eric Balmir, M.S., Pharm.D., CIM, Helen Eldabie, Pharm.D., CDE, Eileen Tang, Pharm.D., BCPS; Pharmacy Department, New York Methodist Hospital, Brooklyn, NY

Pharmacoepidemiology

163. What are the Predictors of Proton Pump Inhibitor Co-Prescription among Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy in Qatar?.

*Dr. Ahmed Awaisu, Ph.D.*¹, Dr. Fatma Hamo, PharmD¹, Lylia Mekideche, BSc (Pharm)², Dr. Nisrine El Muabby, PharmD², Mr. Ahmed M Mahfouz, MSc², Mr. Shaban Mohammed, MSc², Dr. Ahmad Saad, PharmD²; (1)College of Pharmacy, Qatar University, Doha, Qatar; (2)Heart Hospital, Pharmacy Department, Hamad Medical Corporation, Doha, Qatar

Pharmacogenomics/Pharmacogenetics

168. Addition of CYP2C9*5, *6, *8, *11 and rs12777823 genotypes into an existing warfarin dosing algorithm improves algorithm performance for African Americans.

*Katarzyna Drozda, Pharm.D., MS*¹, Shitalben R. Patel, MS¹, Edith A. Nutescu, Pharm.D, MS², Larisa Cavallari, Pharm.D.³; (1)University of Illinois at Chicago College of Pharmacy, Chicago, IL; (2)University of Illinois at Chicago, College of Pharmacy, Chicago, IL; (3)Department of Pharmacotherapy and Translational Research, University of Florida, FL

171. Implementation and evaluation of a *CYP2C19* genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.

*John Andrew Lee, Pharm.D.*¹, Brent N. Reed, Pharm.D., BCPS², David C. Plitt, M.D.³, Jonathan D. Cicci, Pharm.D., BCPS⁴, Kristen E. Tasca, Pharm.D.⁴, Karen E. Weck, M.D.⁵, Craig R. Lee, Pharm.D., Ph.D., FCCP⁶, George A. Stouffer, M.D.⁷; (1)UNC Eshelman School of Pharmacy, Chapel Hill, NC; (2)University of Maryland School of Pharmacy, Baltimore, MD; (3)School of Medicine; University of North Carolina Hospitals and Clinics, Chapel Hill, NC; (4)University of North Carolina Hospitals and Clinics, Chapel Hill, NC; (5)School of Medicine, University of North Carolina, Chapel Hill, NC; (6)Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC; (7)Division of Cardiology, UNC School of Medicine, Chapel Hill, NC

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

173. Impact of high flux dialyzers on vancomycin serum concentrations.

*Joan Mege, Pharm.D.*¹, Dr. Robert Jones, D.O.², Dr. Oluwakemi Fagbami, M.D., Dr. Amal Kebede, D.O., Beth Bechdel, MSN, R.N.; (1)Department of Pharmacy, Reading Hospital, Reading, PA; (2)Section of Infectious Diseases, Reading Health System, Reading, PA

Psychiatry

179. Prescribing trends in Veterans with posttraumatic stress disorder following updated 2010 VA/DoD guidelines.

Abbey N. Loy, Pharm.D., Autumn D. Bagwell, Pharm.D., Jennifer R. Bean, Pharm.D., BCPP, BCPS, Jennifer W. Baker, Pharm.D., BCACP, BCPS, Theron N. Fourakre, Pharm.D., BCPS, Jennifer L. Easterling, Pharm.D.; Veterans Affairs Tennessee Valley Healthcare System, Murfreesboro, TN

Pulmonary

180. Effect of a pharmacist provided education program on the prescribing of maintenance medications for asthma.

Rebecca L. Bragg, PharmD, BCPS, Amie D. Brooks, PharmD, FCCP, BCPS, BCACP, Suzanne G. Bollmeier, PharmD, BCPS, AE-C; St. Louis College of Pharmacy, St. Louis, MO

Rheumatology

183. Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials.

*Vibeke Strand, MD*¹, Sima Ahadi, MS², Jonathan French, ScD³, Jamie Geier, PhD⁴, Sriram Krishnaswami, PhD⁵, Sujatha Menon, PhD⁵, Tina Checchio, PhD², Mary Boy, VMD⁶, Richard Riese, MD, PhD⁵, Juan Gomez-Reino, MD, PhD⁷; (1)Biopharmaceutical Consultant, Portola Valler, CA; (2)Pharmacometrics, Pfizer Inc, Groton, CT; (3)Metrum Research Group, Tariffville, CT; (4)Epidemiology, Pfizer Inc, New York, NY; (5)Pfizer Inc, Groton, CT; (6)Clinical R&D, Pfizer Inc, Groton, CT; (7)Universitario de Santiago, Hospital Clinico, Santiago, Spain

184. Assessment of Lipid Changes and Infection Risk in Diabetic and Nondiabetic Patients with Rheumatoid Arthritis Treated with Tofacitinib.

*W. Rigby, MD*¹, *L. Takiya, PharmD, BCPS*², S. Wood, RN MA³, H. Fan, MS⁴, T. Jones, MD, MPH²; (1)Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center, Lebanon, NH; (2)Pfizer Inc, Collegeville, PA; (3)Pfizer Inc, Groton, CT; (4)Pfizer Inc, Collegeville, CT

185. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis that had inadequate response to non-biologic DMARDs or one or more biologic DMARDs including tumor necrosis inhibitors: pooled analysis from Phase 2 and 3 studies.

*C. Charles-Schoeman, MD*¹, G.R. Burmester, MD², A. Koenig, DO³, J. Maurey, PharmD³, S. Naik, PhD³, *J. Bourret, PharmD*⁴, K. Kwok, MSc⁵, E. Bananis, PhD³, R. Fleischmann, MD⁶; (1)University of California, Los Angeles, Los Angeles, CA; (2)Charité – University Medicine Berlin, Berlin, Germany; (3)Pfizer Inc, Collegeville, PA; (4)Pfizer Inc, Collegeville, CT; (5)Pfizer Inc, New York, NY; (6)Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX

186. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.

J.R. Curtis, MD, MS, MPh¹, H. Schulze-Koops, MD², L. Takiya, PharmD, BCPS³, C. Mebus, PhD⁴, K. Terri, PhD⁵, P. Biswas, PhD⁴, T. Jones, MD, MPh³; (1)University of Alabama at Birmingham, Birmingham, AL; (2)University of Munich, Germany; (3)Pfizer Inc, Collegeville, PA; (4)Pfizer Inc, Groton, CT; (5)Pfizer Inc, New York, NY

187. Reversibility of pharmacodynamic effects after short and long-term treatment with tofacitinib in patients with rheumatoid arthritis.

Mark C. Genovese, MD¹, Thomas T. Kawabata, PhD², Koshika Soma, MD², Sujatha Menon, PhD², James D. Clark, PhD³, Jennifer A. Hodge, PhD⁴, Lisa Takiya, PharmD, BCPS⁵, Richard Riese, MD, PhD², Sriram Krishnaswami, PhD²; (1)Stanford University Medical Center, Stanford, CA; (2)Pfizer Inc, Groton, CT; (3)Pfizer Inc, Cambridge, MA; (4)Pfizer Inc, New York, NY; (5)Pfizer Inc, Collegeville, PA

188. Integrated safety analysis of tofacitinib in rheumatoid arthritis clinical trials with a cumulative exposure of 12,664 patient-years.

S. Cohen, MD¹, Y. Tanaka, MD², X. Marriette, MD³, J.R. Curtis, MD, MS, MPh⁴, K. Kwok, MSc⁵, E.B. Lee, MD⁶, P. Nash, MD⁷, K. Winthrop, MD⁸, C. Charles-Schoeman, MD⁹, K. Thirunavukkarasu, MD¹⁰, A. Anisfeld, PhD⁵, L. Wang, MD¹¹, Richard Riese, MD, PhD¹¹, J. Wollenhaupt, MD¹²; (1)Clinical Research Center, Dallas, TX; (2)University of Occupational and Environmental Health, Kitakyushu, Japan; (3)Paris-Sud University, Paris, France; (4)University of Alabama at Birmingham, Birmingham, AL; (5)Pfizer Inc, New York, NY; (6)Seoul National University, Seoul, South Korea; (7)University of Queensland, Queensland, Australia; (8)Oregon Health and Science University, Portland, OR; (9)University of California, Los Angeles, Los Angeles, CA; (10)Pfizer Australia, Sydney, Australia; (11)Pfizer Inc, Groton, CT; (12)Schoen Klinik Hamburg Eilbek, Hamburg, Germany

Transplant/Immunology

191. Multiple regression analysis of factors associated with neutropenia in steroid-free adult renal transplant recipients taking tacrolimus and mycophenolate in three different study periods during the first year post-transplant.

Tony KL Kiang, BSc(Pharm), PhD, ACPR¹, Nilufar Partovi, PharmD¹, Trana Hussaini, PharmD¹, Rebecca Jean Shapiro, MD², Mary HH Ensom, PharmD, FASHP, FCCP, FCSHP, FCAHS³; (1)Department of Pharmacy, Vancouver General Hospital, Vancouver, BC, Canada; (2)Department of Nephrology, Vancouver General Hospital, Vancouver, BC, Canada; (3)The University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada

192. The Effect of Mycophenolate Mofetil Dose and Trough Levels on Clinical Outcomes in Pediatric Heart Transplant Recipients.

Dr. Carly Mason, PharmD; Department of Pharmacy, Children's Hospital at Montefiore, Bronx, NY

195E. Patient Preferences for Recombinant Human Hyaluronidase (rHuPH20)-Facilitated Subcutaneous (SC) infusion of immunoglobulin G (IGHy) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results.

Diane Ito, MA¹, Xiaolan Ye, PhD², Yan Xiong, MS¹, Josephine Li-McLeod, PhD¹, Richard Schiff, MD, Ph.D³; (1)Baxter HealthCare, Westlake Village, CA; (2)Baxter HealthCare, Deerfield, IL; (3)Baxter Healthcare, Westlake Village, CA

196. A retrospective study of the correlation between tacrolimus exposure and long term outcome in Chinese kidney transplant recipients.

Mr. Chenyu Guo, Master, Prof. Yongxu Sun, Master, Prof. Congxiao Lu, Ph.D, Ms. Wenwen Zheng, Master; Department of Pharmacy, Yuhuangding Hospital, Yantai, China

197. Oral ribavirin for the treatment of paramyxovirus respiratory infections in lung transplant patients.

Alicia Lichvar, PharmD¹, John McDyer, MD², Eun Jeong Kwak, MD³, Joseph Pilewski, MD², Kerry Empey, PharmD, PhD⁴, Christopher R. Ensor, PharmD, BCPS, AQ-CV⁵; (1)Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA; (2)Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; (3)Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA; (4)Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA; (5)Department of Pharmacy & Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA

200. Incidence and risk factors for venous thromboembolism in solid organ transplant recipients.

Chelsea Sammons, PharmD, BCPS, Angela T. Logan, PharmD, BCPS, Christina T. Doligalski, PharmD, BCPS; Department of Pharmacy, Tampa General Hospital, Tampa, FL

CLINICAL PHARMACY FORUM

These abstracts describe the delivery, development, justification, or documentation of an innovative clinical pharmacy service; they may be descriptive only and need not contain an evaluative component.

Adult Medicine

205. Impact of standardized pharmacist involvement in a multidisciplinary delirium intervention team on a general medicine service.

Dr. Anthony Ishak, Pharm.D.¹, Dr. May Adra, Pharm.D.², Mrs. Andrea Branchaud, MPH¹, Dr. Melissa Mattison, MD³; (1)Department of Healthcare Quality, Beth Israel Deaconess Medical Center, Boston, MA; (2)Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA; (3)Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA

206. Impact of a transitions-of-care (TOC) pharmacist on readmission rates and medication compliance in "high-risk" patients.

Dr. Winnie Thi, Pharm.D., Dr. Bayan Yaktien, PharmD, Dr. Harminder Sikand, Pharm.D.; Department of Pharmacy, Scripps Mercy Hospital, San Diego, CA

Ambulatory Care

210. Does Bringing Bottles to Clinic Improve Medication Reconciliation Accuracy.

Dr. Gina J. Ryan, Pharm.D., CDE¹, Jayne Caudle, MLn², Catherine Barnes, Ph.D³, Dr. Heuy Chen, Ph.D⁴, Dr. Nanette Turner, Ph.D.⁴, Dr. David Ziemer, MD²; (1)Department of Pharmacy Practice, Mercer University College of Pharmacy, Atlanta, GA; (2)Department of Medicine, Division of Endocrinology and Metabolism, Emory University School of Medicine, Atlanta, GA; (3)Department of Medicine, Division of Endocrinology and Metabolism, Emory University School of Medicine, Atlanta; (4)Department of Public Health, Mercer University College of Health Professions, Atlanta, GA

211. Development and implementation of a multi-disciplinary clinic for transition of care (TOC) following hospital discharge in Medicare Advantage Plan members.

*Grace Ancheta, Pharm.D.*¹, Jinwen Li, Pharm.D., BCACP², Tracy Lin, Pharm.D., CACP, BCACP³, Alexis Ryon, Pharm.D., BCACP⁴, Michelle Cavner, Pharm.D.², Heather Jaeger, Pharm.D., CACP²; (1)Cigna Medical Group, Sun City, AZ; (2)Cigna Medical Group, Phoenix, AZ; (3)Cigna Medical Group, Mesa, AZ; (4)Cigna Medical Group, Glendale, AZ

212. Justification for implementation of a pharmacist-managed Medicare annual wellness visit clinic.

*Karen Sando, Pharm.D., BCACP, CDE*¹, Jonathan Grant Harrell, MD²; (1)Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL; (2)Department of Community Health and Family Medicine/Family Medicine at Old Town, University of Florida College of Medicine, Old Town, FL

213. Development and implementation of clinical pharmacy services within an outpatient pulmonary clinic.

*Dr. Amber Lanae Smith, PharmD, MSc, BCPS*¹, Nancy MacDonald, PharmD, BCPS², Dr. Krishna Thavarajah, MD, MSc³, Dr. Bruno DiGiovine, MD, MPH⁴, James S. Kalus, PharmD, BCPS, (AQ-Cardiology)²; (1)Department of Pharmacy Practice, Wayne State University, Detroit, MI; (2)Henry Ford Hospital, Detroit, MI; (3)Department of Pulmonology, Henry Ford Hospital, Detroit, MI; (4)Division of Pulmonary, Critical Care, and Sleep Medicine, Henry Ford Hospital, Detroit, MI

214. Impact of a Pharmacist-Managed Smoking Cessation Program.

Dr. Kelly Wright, PharmD, BCACP, TTS; School of Pharmacy, Cedarville University, Cedarville, OH

220. Development of a Patient Care Standard in a Multi-site PGY1 Pharmacy Residency in Ambulatory Care.

Anita Sharma, Pharm.D., Sarah Westberg, Pharm.D., BCPS; University of Minnesota College of Pharmacy, Minneapolis, MN

Cardiovascular

221E. Infectious complications associated with induced hypothermia for cardiac arrest.

Kerry Schueler, PharmD, Ryan Hobbs, BS Pharm; Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, IA

223. Outcomes associated with restricted use of sodium bicarbonate when compared with normal saline for the prevention of contrast-induced nephropathy.

*Dr. Oksana Barakat, PharmD, BCPS-AQ-Card*¹, Dr. Haywood Rhodes, PharmD¹, Jenna M. Huggins, PharmD, BCPS²; (1)Department of Pharmacy, WakeMed Health & Hospitals, Raleigh, NC; (2)WakeMed Health and Hospitals, Raleigh, NC

Community Pharmacy Practice

228. Community pharmacists' attitudes toward Dispensing errors at community pharmacy setting in Central Saudi Arabia.

Mohamed Alarifi, PhD; Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

229. Community pharmacist's role in a county-wide health initiative aimed at decreasing the incidence of type 2 diabetes.

*Robin Parker, PharmD*¹, Ben Gross, PharmD, CDE, BCPS, BCACP, BC-ADM², Richard Randolph, PharmD¹; (1)Marcrom's Pharmacy, Manchester, TN; (2)Department of Pharmacy Practice, Lipscomb University College of Pharmacy, Nashville, TN

Critical Care

230E. Efficacy and safety of high dose dexmedetomidine in cardiac and medical intensive care patients.
Deanna Bice, PharmD, BCPS, April Quidley, PharmD, BCPS, FCCM, Chad Alligood, PharmD, Rena Beth Morse, PharmD, Christy Forehand, PharmD, BCPS; Vidant Medical Center, Greenville, NC

231. Characterization of Intervention Rates by Expanded, After-hour, Decentralized Critical Care Pharmacy Services at an Academic Medical Center.

Erik J. Rachwalski, PharmD, BCPS, Bryan D. Lizza, PharmD, BCPS, Kasey M. Greathouse, PharmD, BCPS, Deepika R. Pereira, PharmD, BCPS, Kimberly Lévasseur-Franklin, PharmD, BCPS, Kristen March, PharmD, BCPS, Michael Postelnick, RPh, BCPS (AQ ID); Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL

Education/Training

236. Pharmacy Education in Saudi Arabia towards Clinical Teaching and Practice.

Prof. Yousif Asiri, Ph.D.; Clinical Pharmacy Department, College of Pharmacy - King Saud University, Riyadh, Saudi Arabia

237. Providing pharmacy services in third world countries.

Michelle Holm, PharmD., BCPS; Mayo Clinic, Rochester, MN

241. The implementation of an advance pharmacy practice experiential student program at a supply chain management organization.

Shaffeeulah Bacchus, Pharm.D.; Pharmacy Department, Yankee Alliance Inc, Andover, MA

242. Active Learning Simulation Preparing Students for Community Pharmacy: A Peer Teaching Experience.

*Dr. Melissa Ruble, Pharm.D.*¹, Dr. Jaclyn Cole, Pharm.D.¹, Dr. Erini Serag-Bolos, Pharm.D.²; (1)Pharmacotherapeutics and Clinical Research Department, University of South Florida College of Pharmacy, Tampa, FL; (2)Pharmacotherapeutics and Clinical Research, University of South Florida College of Pharmacy, Tampa, FL

Emergency Medicine

245. Appropriateness of post-exposure rabies prophylaxis in a community hospital emergency department.

Dr. Kimball Owens, Pharm.D., BCPS, Dr. Dustin Waters, Pharm.D., BCPS, Dr. Tyson Bigelow, Pharm.D., BCPS, Dr. Britta Bergstrom, Pharm.D., BCPS, Dr. Aleesha Galeria, Pharm.D., BCPS, Dr. Christian Larsen, Pharm.D., BCPS; Intermountain Healthcare, Ogden, UT

Family Medicine

248E. Call me maybe? A pharmacist-managed, telephonic transitions of care program in a patient centered medical home (PCMH): effect on hospital readmission.

Amanda Wojtusik, PharmD, BCPS¹, Jennie Broders, PharmD, BCPS²; (1)Department of Medical Education, UPMC St. Margaret, Pittsburgh, PA; (2)UPMC St. Margaret Family Medicine Residency Program, UPMC St. Margaret, Pittsburgh, PA

249. Prospective Pharmacist Identification of Drug Therapy Problems in the Medical Home.

Dr. Tamara Lallier, Pharm.D., MBA¹, James D. Hoehns, Pharm.D., BCPS, FCCP²; (1)Northeast Iowa Medical Education Foundation/Waverly Health Center, Waterloo, IA; (2)University of Iowa College of Pharmacy and Northeast Iowa Family Practice Center, Waterloo, IA

Gastroenterology

250. Pharmacy Coordinated Prescribing of Hepatitis C Medications in an Ambulatory Care Clinic.

Dr. David Quan, Pharm.D., Dr. Aileen Chi, Pharm.D.; Department of Pharmaceutical Services, UCSF Medical Center, San Francisco, CA

Geriatrics

251. Program of all-inclusive care for the elderly: an evaluation of enrollee physical health outcomes and impact of pharmacist involvement on chronic disease state management.

Macey Williams, Pharm.D.¹, Amber Lanae Smith, Pharm.D., BCPS¹, Prabha Dhanapal, Pharm.D., BCPS, BCOP¹, Megan Mills, Pharm.D., CGP², Donna Beydoun, Pharm.D., CGP³; (1)Department of Pharmacy Services, Henry Ford Hospital, Detroit, MI; (2)Center for Senior Independence; (3)Merck

Health Services Research

253. Determining the Impact of a New Medication-History Pharmacy Technician Program.

Kayta Kobayashi, PharmD, BCPS, Huong Le, PharmD; Department of Pharmacy Services, Memorial-Hermann Hospital, Houston, TX

HIV/AIDS

261. Statin Use in the ATP III Guidelines Compared to the 2013 ACC/AHA Guidelines in HIV Primary Care Patients.

Anges Cha, pharm D, Elise Kim, pharm D, Pansy Elsamadisi, pharm D, Safia Latif, pharm D; Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University,

262E. Analysis of baseline HIV-1 genotypes in naïve subjects with HIV in a correctional setting.

Dr. Melissa E. Badowski, PharmD¹, Ryan Werner, PharmD Candidate², Dr. Jeremy Young, MD, MPH³, Pyrai Vaughn, MA³, Dr. Louis Shicker, MD⁴, Dr. Mahesh Patel, MD³; (1)University of Illinois at Chicago College of Pharmacy, Chicago, IL; (2)University of Illinois at Chicago, College of Pharmacy; (3)University of Illinois at Chicago, College of Medicine; (4)Illinois Department of Corrections

Infectious Diseases

265. Evaluation of a Novel Vancomycin vs. Linezolid ICU Cycling Protocol in Documented MRSA Nosocomial Pneumonia.

*Nikunj Vyas, PharmD*¹, Douglas Slain, Pharm.D., BCPS², Lisa Keller, Pharm.D.³, Arif R. Sarwari, MD, MSc, MBA⁴; (1)West Virginia University Healthcare, Morgantown, WV; (2)West Virginia University School of Pharmacy, Morgantown, WV; (3)West Virginia University Healthcare; (4)Department of Medicine, Section of Infectious Diseases, West Virginia University, Morgantown, WV

266. Reduced levofloxacin utilization following revision of electronic community-acquired pneumonia order sets and provider education as part of an inpatient antimicrobial stewardship program initiative. *Dr. Brad R. Laible, Pharm.D., BCPS-AQ ID*¹, Dr. Kathryn Dzintars, Pharm.D., BCPS², Dr. Jawad Nazir, MD¹; (1)Avera McKennan Hospital and University Health Center, Sioux Falls, SD; (2)The Johns Hopkins Hospital, Baltimore, MD

268. Provider acceptance and impact of a consultative, non-coercive antimicrobial stewardship program at a Veterans Affairs medical center.

*Pamela A. Foral, Pharm.D., BCPS*¹, Elizabeth Jamieson, Pharm.D.², Marvin Bittner, MD³, Gary Gorby, MD³, Edward Horowitz, MD³, Karim Ali, MD³, Kari Neeman, MD³, Renuga Vivekanandan, MD³, Cezarina Mindru, MD³, Mir Ali, M.D.³, Michaela Hrdy, Pharm.D.², John Horne, MD³, Leo Dobronski, MD³, Laurel Preheim, MD³; (1)Creighton University School of Pharmacy and Health Professions, Omaha, NE; (2)Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE; (3)Creighton University School of Medicine, Omaha, NE

Medication Safety

276. Drug disposal: What can we learn from the contents of a drug disposal drop box?

*Jayne Pawasauskas, PharmD*¹, Kelly Matson, BSNutr, PharmD², Emily Matthew, PharmD³; (1)University of Rhode Island, Kingston, RI; (2)Department of Pharmacy Practice, University of Rhode Island, Kingston, RI; (3)University of Rhode Island College of Pharmacy

277. What do Patients do With Their Prescription Medications? Pooled Analysis from 4 Medication Safety Studies.

*Jayne Pawasauskas, PharmD*¹, *Kelly Matson, BSNutr, PharmD*²; (1)University of Rhode Island, Kingston, RI; (2)Department of Pharmacy Practice, University of Rhode Island, Kingston, RI

278. Evaluation of medication reconciliation conducted by clinical pharmacists at a newly established hospital in Qatar.

*Dr. Hala Sonallah, PharmD*¹, *Mr. Tarek Ibrahim, MCLinPharm*¹, Prof. Mohamed Izham MI, PhD²; (1)Clinical Pharmacy, Al-Wakra Hospital: Hamad Medical Corporation, Al-Wakra, Qatar; (2)College of Pharmacy, Qatar University, Doha, Qatar

Other

281. Highlights of the history and achievements of the Ambulatory Care PRN.

*Catherine Bourg, Pharm.D.*¹, *Maria Thurston, Pharm.D.*², *Emily McCoy Armstrong, Pharm.D., BCACP*³, *Stephanie Nigro, Pharm.D.*⁴, *Robin Koffarnus, Pharm.D.*⁵, *Marissa Quinones, Pharm.D.*⁶; (1)University of Georgia College of Pharmacy, Athens, GA; (2)Mercer University; (3)Auburn University Harrison School of Pharmacy Mobile Campus, Mobile, AL; (4)MCPHS University; (5)TTUHSC; (6)Southeast Dallas Health Center

282. The Intersection of Pharmacy and Global Health.

Dr. Diane Nguyen, PharmD; Ernest Mario School of Pharmacy, The State University of New Jersey, Rutgers, Spring, TX

Pharmacoeconomics/Outcomes

285. Application of piperacillin/tazobactam extended dosing strategy to improve clinical and cost effectiveness in the presence of a drug shortage.

Shaffeeulah Bacchus, Pharm.D; Pharmacy Department, Yankee Alliance Inc, Andover, MA

LATE BREAKERS

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

Cardiovascular

426. Evaluation of the safety and efficacy of prophylactic amiodarone therapy for prevention of postoperative atrial fibrillation in patients who underwent cardiothoracic surgery.

Dr. Danny Ephraim Jr., Pharm.D.¹, Dr. Alison Stevens, Pharm.D., BCPS¹, Anastasia Armbruster, Pharm.D., BCPS²; (1)Missouri Baptist Medical Center, Saint Louis, MO; (2)St. Louis College of Pharmacy, Saint Louis, MO

427. Effects of Long Term Proton Pump Inhibitor Use in Those Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.

Penelope Bland, B.A.¹, Kelly C. Rogers, Pharm.D.², Shannon W. Finks, Pharm.D.²; (1)College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN; (2)Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis, TN

Education/Training

428. Improvement in pharmacy students' familiarity with tackling the challenges of the community pharmacy setting after a simulation activity.

Jose Barboza, Pharm.D., C.D.E.¹, Wen-Yi Jiang, Pharm.D., B.C.P.S.², Sarah Steinhardt, PharmD, JD³; (1)Pharmacotherapeutics and Clinical Research, University of South Florida College of Pharmacy, Tampa, FL; (2)CVS, FL; (3)University of South Florida College of Pharmacy

Endocrinology

431. Cardiovascular risk associated with dipeptidyl peptidase-4 inhibitors compared with metformin.

Chun-Nan Kuo, Master, Ya-Leng Lin, Pharm.D, Man-Tzu Wu, Pharm.D; Wan Fang Hospital, Taipei Medical University

Family Medicine

432. Improving health of at-risk rural patients (IHARP): Interim clinical outcomes associated with a novel comprehensive coordinated care model.

Dr. Karen Williams, PharmD¹, Dr. Leticia R. Moczygemba, PharmD, PhD², Dr. Andrea L. Pierce, PharmD², Dr. Tanvi Patil, PharmD¹, Dr. Nikisa Blevins, PharmD¹, Dr. Heidi Wengerd, PharmD¹, Dr. Courtney Dickerson, PharmD¹, Dr. Kelley Mills, PharmD¹, Dr. Ann Lucktong, PharmD¹, Dr. Randi Carpenter, PharmD¹, Dr. Michael Czar, PhD, RPh¹, Dr. William Lee, BPharm, MPA¹, Dr. Gary R. Matzke, PharmD²; (1)Carilion New River Valley Medical Center; (2)Department of Pharmacotherapy and Outcomes Sciences, Virginia Commonwealth University School of Pharmacy, Richmond, VA

HIV/AIDS

434. Virologic Outcomes with Elvitegravir (EVG) and Raltegravir (RAL) in an Urban Cohort.
Dr. Siddharth Swamy, Pharm.D.¹, Prof. Roopali Sharma, Pharm.D., BCPS (AQ-ID), AAHIVP², Prof. Agnes Cha, Pharm.D., AAHIVP, BCACP², Dr. Jameela Yusuff, MD, MPH, FACP³; (1)Depart of Pharmacy, SUNY Downstate Medical Center; (2)Long Island University; (3)Division of Infectious Diseases, SUNY Downstate Medical Center

Infectious Diseases

435. Assessing the impact of Computerized Physician Order Entry (CPOE) upon adherence to Center for Medication Safety (CMS) core measures for empiric treatment of community-acquired pneumonia (CAP) at a community hospital.
Virginia Fleming, PharmD, BCPS, Robin Southwood, PharmD, BCPS, CDE; Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, GA

Medication Safety

436. Impact of Intensive Pharmacotherapeutics on emergency department medication reconciliation: a novel clinical pharmacy practice model.
Dr. Amanda Winans, PharmD, Dr. Amanda Engle, PharmD; Bassett Medical Center, Cooperstown, NY

Pain Management/Analgesia

439. Efficacy and Safety of Extended-Release Tramadol for Osteoarthritis: A Meta-analysis.
Ms. Yuan Xue, M.S., Mr. Xiaobin Zhu, B.S., Mr. Jiangfeng Wang, M.S., Mrs. Ke Ma, B.S.; Department of pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Pharmacoeconomics/Outcomes

440. Assessing the Quality of Reporting Medication Adherence in Published Clinical Trials.
Dr. Emily Tabinski, Pharm.D.; VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM

Pharmacoepidemiology

441E. Metoclopramide Prescription and Neurological Side Effects in Adult Taiwanese Patients.
Shin-Chia Tsai, M.S.¹, Rey-Yue Yuan, M.D.², Shioh-Yunn Sheu, Ph.D.³, You-Meei Lin, M.S.¹, Meng-Ting Hsu, M.S.¹; (1)Department of Pharmacy, Shuang Ho Hospital, Taipei Medical University, New Taipei City,

Taiwan; (2)Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; (3)School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan